MA29787B1 - Traitement de maladies auto-immunes - Google Patents

Traitement de maladies auto-immunes

Info

Publication number
MA29787B1
MA29787B1 MA30758A MA30758A MA29787B1 MA 29787 B1 MA29787 B1 MA 29787B1 MA 30758 A MA30758 A MA 30758A MA 30758 A MA30758 A MA 30758A MA 29787 B1 MA29787 B1 MA 29787B1
Authority
MA
Morocco
Prior art keywords
autoimmune diseases
treatment
methods
sclerosis
ureity
Prior art date
Application number
MA30758A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29787B1 publication Critical patent/MA29787B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION PORTE SUR DES MÉTHODES DE TRAITEMENT DE DIVERSES MALADIES AUTO-IMMUNES, TELLES QUE LA SCLÉROSE EN PLAQUE, LA NÉVRITE PÉRIPHÉRIQUE, LA NÉVRITE OPTIQUE, LA SCLÉROSE AMYOTROPHIQUE LATÉRALE ET L'UVÉITE, CES MÉTHODES UTILISANT DES DÉRIVÉS AMINO-ALCOOL SPÉCIFIQUES.
MA30758A 2005-09-09 2008-03-17 Traitement de maladies auto-immunes MA29787B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
MA29787B1 true MA29787B1 (fr) 2008-09-01

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30758A MA29787B1 (fr) 2005-09-09 2008-03-17 Traitement de maladies auto-immunes

Country Status (28)

Country Link
US (1) US20080200438A1 (fr)
EP (2) EP1926483B1 (fr)
JP (4) JP5244598B2 (fr)
KR (3) KR101476591B1 (fr)
CN (1) CN101257899B (fr)
AT (1) ATE489948T1 (fr)
AU (2) AU2006289100B2 (fr)
BR (1) BRPI0615906A2 (fr)
CA (2) CA2820510A1 (fr)
CY (1) CY1111285T1 (fr)
DE (1) DE602006018629D1 (fr)
DK (2) DK1926483T3 (fr)
ES (2) ES2529724T3 (fr)
IL (2) IL189665A (fr)
JO (1) JO2655B1 (fr)
MA (1) MA29787B1 (fr)
MX (1) MX2008003170A (fr)
NO (1) NO20081727L (fr)
NZ (2) NZ588372A (fr)
PL (2) PL1926483T3 (fr)
PT (2) PT2295049E (fr)
RU (2) RU2424795C2 (fr)
SG (1) SG165364A1 (fr)
SI (2) SI2295049T1 (fr)
TN (1) TNSN08103A1 (fr)
TW (2) TWI372620B (fr)
WO (1) WO2007028821A2 (fr)
ZA (1) ZA200801694B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
AU2005292984B2 (en) 2004-10-12 2011-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
RU2421214C2 (ru) * 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2305305A4 (fr) * 2008-05-20 2013-02-13 Kyorin Seiyaku Kk Agent d'induction/d'entretien de rémission
CA2734585A1 (fr) * 2008-08-18 2010-02-25 Novartis Ag Derives d'amino-alcools destines au traitement de neuropathies peripheriques demyelinisantes
NZ603999A (en) * 2010-05-06 2014-06-27 Novartis Ag Treatment of autoimmune diseases
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003264430B2 (en) * 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
KR100995486B1 (ko) * 2002-09-28 2010-11-22 맥네일-피피씨, 인코포레이티드 개구가 있는 쉘을 포함하는 속방성 투여형
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
DE202004021680U1 (de) * 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
WO2005014525A2 (fr) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
MXPA06002349A (es) * 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
KR20140117704A (ko) 2014-10-07
IL189665A (en) 2014-07-31
CY1111285T1 (el) 2015-08-05
SI2295049T1 (sl) 2015-03-31
KR20080046231A (ko) 2008-05-26
HK1149906A1 (en) 2011-10-21
DK2295049T3 (en) 2015-02-23
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
JP2013010802A (ja) 2013-01-17
CA2620554A1 (fr) 2007-03-15
EP1926483A2 (fr) 2008-06-04
PL1926483T3 (pl) 2011-05-31
RU2424795C2 (ru) 2011-07-27
JO2655B1 (en) 2012-06-17
TW200803829A (en) 2008-01-16
AU2006289100A1 (en) 2007-03-15
IL233328A0 (en) 2014-08-31
CN101257899A (zh) 2008-09-03
PT1926483E (pt) 2011-03-03
AU2010224355B2 (en) 2012-03-29
EP1926483B1 (fr) 2010-12-01
KR20140019033A (ko) 2014-02-13
IL189665A0 (en) 2008-06-05
PT2295049E (pt) 2015-03-02
TWI376223B (en) 2012-11-11
CA2620554C (fr) 2013-12-17
TNSN08103A1 (en) 2009-07-14
KR101476451B1 (ko) 2014-12-24
RU2011111117A (ru) 2012-09-27
RU2493840C2 (ru) 2013-09-27
EP2295049A1 (fr) 2011-03-16
BRPI0615906A2 (pt) 2011-05-31
CA2820510A1 (fr) 2007-03-15
SI1926483T1 (sl) 2011-04-29
NO20081727L (no) 2008-06-06
SG165364A1 (en) 2010-10-28
CN101257899B (zh) 2012-10-03
ES2357426T3 (es) 2011-04-26
NZ588372A (en) 2012-03-30
TWI372620B (en) 2012-09-21
NZ566137A (en) 2011-05-27
JP2017019854A (ja) 2017-01-26
DK1926483T3 (da) 2011-03-14
JP2009507810A (ja) 2009-02-26
ATE489948T1 (de) 2010-12-15
EP2295049B1 (fr) 2014-11-26
RU2008113187A (ru) 2009-10-20
JP5244598B2 (ja) 2013-07-24
AU2010224355A1 (en) 2010-10-14
AU2006289100B2 (en) 2010-07-22
WO2007028821A3 (fr) 2007-05-03
ZA200801694B (en) 2009-09-30
WO2007028821A2 (fr) 2007-03-15
TW201034659A (en) 2010-10-01
JP2015025002A (ja) 2015-02-05
DE602006018629D1 (de) 2011-01-13
ES2529724T3 (es) 2015-02-25
PL2295049T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
ATE368031T1 (de) Neue gamma secretase inhibitoren
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
EA200802054A1 (ru) Ингибиторы фермента
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0408491A (pt) tratamento da doença de alzheimer
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
EP2073635A4 (fr) Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
BG108033A (bg) Използване на 2-амино-1-(4-хидрокси-2-метансулфонамидофенил) етанол за лечение на инконтиненция
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
TH45761A (th) สารยับยั้งระบบการตัดไกลซีนที่มีศักยภาพเป็นสารต้านโรคจิต